PROM1 and acute lymphoblastic leukemia: Interestingly, we observed no clear correlation of CD133+ blasts in B-ALL patients with a higher risk profile compared to standard risk, indicating that 293C3-SDIE could be used independently of risk association in B-ALL patients.